Abstract Details
Activity Number:
|
31
|
Type:
|
Contributed
|
Date/Time:
|
Sunday, August 4, 2013 : 2:00 PM to 3:50 PM
|
Sponsor:
|
Biopharmaceutical Section
|
Abstract - #309724 |
Title:
|
Bivariate Continual Reassessment Method (BCRM) Applied to Oncology Dose Escalation Study
|
Author(s):
|
Yinghua (Grace) Zhang*+ and Jie Ding
|
Companies:
|
GSK and GSK
|
Keywords:
|
BCRM ;
CRM ;
dose escalation ;
oncology ;
monoclonal antibody
|
Abstract:
|
The traditional dose escalation study in Oncology based solely on toxicity and without regard to the drug's efficacy. We propose extending the continual reassessment method (CRM) to a bivariate study design which the optimal dose recommended to expansion cohort is based jointly on both toxicity and efficacy. We call this study design Bivariate Continual Reassessment Method (BCRM) and demonstrate through simulation the BCRM has excellent operation characteristics compared to the traditional dose escalation study. We also demonstrate the BCRM will have potential wide application to monoclonal antibodies in Oncology when the therapeutic window is much lower than the maximum tolerated dose (MTD) or MTD cannot be reached practically.
|
Authors who are presenting talks have a * after their name.
Back to the full JSM 2013 program
|
2013 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.
The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Copyright © American Statistical Association.